Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novo Nordisk A/S Class B (NOVOb)

Copenhagen
Currency in DKK
Disclaimer
881.3
-7.0(-0.79%)
Closed

NOVOb Comments

My investment propensity test was surprising that Jim Simon, a Renaissance technology, had the most stocks he owned, but it was even more surprising that Novo Nordisk AS. Because it was the only event I recommended to my friend. HHH
Boooooom! 30%.
Very very bullish!
Those dislikes didnt age well🙂
Dislikes dont know anything obviously
Does anyone no of a particular reason that NOVO B is going so far down today? Is it profit taking before Q1 2022 results?
I used to do the same thing. In the case of novice investment, we try to find out the reason for the fall and rise in stock prices. It's a futile act. The rise and fall in stock prices are just for Manipulators to move in a predetermined scenario. So a successful investment is a quick insight into Manipulators' scenarios. HHH
New Target 825 by EOM
New Target 825
Consolidating nicely for leg up to 850!🌟
Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
bullish??
No. Funds are selling. Time to wait to go long...
Perfect opportunity to make short,,
can you explain why please?
No explaning? 🤷
because he has no explanation. Novo nordisk is a soli long-term stock. I know a lot about opioid treatments, and methadon is changing to lipo-methadon, wich has really only one competitor on the global field. That competitor is Camurus AB with their product buvidol. I tecommend to all investors to buy and HOLD for these two companies, because there is no other options for a opioid-replacement-care, except Suboxone, and that is going to be replaced Lipo-methadon or Buvidol, at least here in Finland. Suboxone is manufactured for Indivor Inc, by Aquestive Therapeutics, if someone wants to do a little research.
Bullish sentiment.
Why is going so low???
Anyone got a view on how much the Trump/US plans to reduce medical prices will affect the share price?
Extremely bullish double bottom pattern and fibbonacci retracement with convergence of relative strenght index upwards
Comenté hace unos meses que es un valor muy sólido, que lo veríamos pronto en 200 $ (que con el split son 40 $), pues bien, ha superado mis expectativas y está en 45 $.... me aventuro a pronosticar que cerrará el año en torno a los 50 $. Saludos
Comenté hace unos meses que es un valor muy sólido, que lo veríamos pronto en 200 $ (que con el split son 40 $), pues bien, ha superado mis expectativas y está en 45 $.... me aventuro a pronosticar que cerrará el año en torno a los 50 $. Saludos
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.